Plain-English translation of NCT06548529 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study tests a new type of imaging scan called an Al18F-HER2-BCH PET/CT scan in patients with bladder cancer who are being treated with an anti-HER2 ADC medication. The scan uses a special radioactive tracer to measure how much HER2 protein is present in cancer cells, which may help doctors predict whether the medication will work well for you. Researchers want to understand if this scan can help guide treatment decisions and predict outcomes.
Current methods don't reliably predict which patients will respond best to this new bladder cancer medication. This trial aims to develop a better imaging tool that could help doctors personalize treatment and identify patients most likely to benefit from the medication before or early in their treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive a specialized PET/CT imaging scan called an Al18F-HER2-BCH scan while continuing your anti-HER2 ADC medication treatment. The scan involves receiving an injection of a radioactive tracer and then lying still in a scanner for about 30 minutes so doctors can see how much HER2 protein is in your cancer cells. This scan will help researchers determine if the imaging results can predict how well the medication is working for you.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China